EditorialPolicy

Trimi publishes educational pages about weight management, compounded GLP-1 treatments, telehealth access, treatment logistics, pricing context, medication safety, and patient preparation.

Our goal is to make complex health information easier to understand without replacing personalized medical advice from a licensed clinician. Content on this site is intended to support informed questions and safer decision-making, not self-diagnosis or self-prescribing.

Trimi content is drafted by the editorial team and clinical content contributors based on the topic, search intent, and the level of medical risk involved.

We prioritize plain-language explanations, transparent limitations, and practical patient guidance. When content addresses medications, side effects, contraindications, dosing, eligibility, or treatment safety, it is held to a higher review standard before publication or significant updates.

For clinical and regulatory topics, Trimi aims to rely on primary or high-authority sources whenever possible, including prescribing information, FDA communications, peer-reviewed literature, and recognized medical guidance.

Recurring sources include the Endocrine Society's 2024 Clinical Practice Guideline on pharmacological management of obesity in adults, the AACE Comprehensive Type 2 Diabetes Management Algorithm 2024, FDA prescribing information for the brand-name finished products containing semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound), and primary trial publications including STEP 1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), SELECT (NEJM 2023), and SURPASS-2 (NEJM 2021).

We avoid overstating outcomes, omitting meaningful safety context, or presenting marketing copy as clinical evidence. When evidence is limited, evolving, or context-dependent, our content should say so clearly.

Trimi's named clinical reviewer is Dr. Asad Niazi, MD, MPH, who reviews patient eligibility and clinical content through the Beluga Health 50-state physician network. Beluga Health serves as Trimi's multistate medical service organization (MSO), maintaining state-by-state licensure and credentialing for the prescribers who handle patient intakes on this platform.

Compounded prescriptions are dispensed by Trimi's named 503A community sterile compounding pharmacy partners: VialsRx (Texas State Board pharmacy license #35264, fulfills the majority of Trimi prescriptions) and GreenwichRx. Both pharmacies are FDA-overseen and operate under current Good Manufacturing Practice (cGMP) standards.

Trimi's compounded preparations are prepared per individual prescription and are not themselves FDA-approved as drugs. The active pharmaceutical ingredients — semaglutide and tirzepatide — are FDA-approved in the corresponding brand-name finished products. Editorial content distinguishes between the compounded preparations available through Trimi and the brand-name finished products available elsewhere; content that conflates the two is corrected.

For details on which pages receive additional clinical accuracy review and what reviewers check, see our Medical Review Policy.

We update pages when there are meaningful changes to treatment availability, pricing structure, safety guidance, clinical expectations, or internal care processes. Many articles also display publish dates, last updated dates, or medical review dates to help readers understand recency.

If we identify an inaccuracy, outdated statement, or ambiguous claim, we revise the page as quickly as practical. Readers can request a correction or clarification by contacting care@trytrimi.com.

Trytrimi.com includes marketing, education, and product information related to Trimi services. That means some pages may discuss Trimi programs directly, but promotional goals do not override safety, accuracy, or disclosure requirements.

Site content does not create a patient-provider relationship on its own. Treatment decisions are made only after review by a licensed medical professional through the clinical care process.